Kala Pharmaceuticals to Report Second Quarter 2020 Financial Results and Host Conference Call
July 30 2020 - 4:01PM
Business Wire
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical
company focused on the discovery, development and commercialization
of innovative therapies for diseases of the eye, today announced
that it will report second quarter 2020 financial results on
Thursday, August 6, 2020. Management will host a conference call
and live audio webcast to discuss these results and provide a
business update at 8:00 a.m. ET.
The dial-in numbers to access the conference call are
866-300-4091 (domestic) or 703-736-7433 (international) using the
conference ID 6999350. To access a live webcast and subsequent
archived recording of the call, please visit the “Investors &
Media” section on the Kala website at http://kalarx.com/.
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the discovery,
development and commercialization of innovative therapies for
diseases of the eye. Kala has applied its AMPPLIFYTM mucus
penetrating particle Drug Delivery Technology to a corticosteroid,
loteprednol etabonate (LE), designed for ocular applications,
resulting in the January 2019 launch of INVELTYS® (loteprednol
etabonate ophthalmic suspension) 1% and its investigational product
candidate, EYSUVISTM (loteprednol etabonate ophthalmic suspension)
0.25%, for which a New Drug Application (NDA) is under review by
the United States Food and Drug Administration (FDA) with a
Prescription Drug User Fee Act (PDUFA) goal date set for October
30, 2020.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200730005729/en/
Investor Contact: Hannah Deresiewicz
hannah.deresiewicz@sternir.com 212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Jun 2024 to Jul 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Jul 2023 to Jul 2024